A more detailed understanding of the somatic genetic events that drive gastrointestinal
adenocarcinomas is necessary to improve diagnosis and
therapy. Using data from high-density genomic profiling arrays, we conducted an analysis of somatic copy-number aberrations in 486 gastrointestinal
adenocarcinomas including 296 esophageal and
gastric cancers. Focal amplifications were substantially more prevalent in gastric/esophageal
adenocarcinomas than
colorectal tumors. We identified 64 regions of significant recurrent amplification and deletion, some shared and others unique to the
adenocarcinoma types examined. Amplified genes were noted in 37% of gastric/esophageal
tumors, including in therapeutically targetable
kinases such as ERBB2, FGFR1, FGFR2, EGFR, and MET, suggesting the potential use of genomic amplifications as
biomarkers to guide
therapy of gastric and
esophageal cancers where targeted
therapeutics have been less developed compared with
colorectal cancers. Amplified loci implicated genes with known involvement in
carcinogenesis but also pointed to regions harboring potentially novel cancer genes, including a recurrent deletion found in 15% of esophageal
tumors where the Runt
transcription factor subunit RUNX1 was implicated, including by functional experiments in tissue culture. Together, our results defined genomic features that were common and distinct to various gut-derived
adenocarcinomas, potentially informing novel opportunities for targeted therapeutic interventions.